UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the month of March 2020

Commission File Number: 001-31368

SANOFI

(Translation of registrant’s name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐            No  ☒

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-             


In March 2020, Sanofi issued the press releases attached hereto as Exhibit 99.1, 99.2, 99.3 and 99.4 which are incorporated herein by reference.

Exhibit List

 

Exhibit
    No.    

  

Description

Exhibit 99.1    Press release dated March 30, 2020: First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
Exhibit 99.2    Press release dated March 27, 2020: Sanofi receives positive CHMP opinion for Sarclisa® (isatuximab) for the treatment of relapsed and refractory multiple myeloma
Exhibit 99.3    Press release dated March 27, 2020: Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19
Exhibit 99.4    Press release dated March 24, 2020: Sanofi successfully prices EUR 1.5 billion of bond issue


Exhibit Index

 

Exhibit
    No.    

  

Description

Exhibit 99.1    Press release dated March 30, 2020: First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
Exhibit 99.2    Press release dated March 27, 2020: Sanofi receives positive CHMP opinion for Sarclisa® (isatuximab) for the treatment of relapsed and refractory multiple myeloma
Exhibit 99.3    Press release dated March 27, 2020: Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19
Exhibit 99.4    Press release dated March 24, 2020: Sanofi successfully prices EUR 1.5 billion of bond issue


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: March 30, 2020               SANOFI
    By    

/s/ Alexandra Roger

    Name:   Alexandra Roger
    Title:  

Head of Securities Law and

Capital Markets

Sanofi (PK) (USOTC:SNYNF)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Sanofi (PK) Charts.
Sanofi (PK) (USOTC:SNYNF)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Sanofi (PK) Charts.